AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 AUG 22 - (NewsRx.com & NewsRx.net) -- Findings released from the heart and estrogen/progestin replacement study follow-up (HERS II), and published in the Journal of the American Medical Association (JAMA), address the use of hormone replacement therapy (HRT) by older women with heart disease, not the typical woman on HRT.
All of the women who participated in the HERS II study had serious heart disease and average age 71 at the start of the study. In contrast, the average age of the typical woman at the onset of menopause is 51.
Based on information from a large HMO claims database, less than 6% of the women on hormone replacement therapy have heart disease. In addition, most of the women in HERS II were also taking other medications (such as statins) to control their heart disease, making it very difficult to detect any incremental effect due to hormone therapy.
An open-label, unblinded follow-up to the randomized, placebo-controlled 1998 HERS trial, HERS II found that in women with heart disease, hormone replacement therapy neither worsened nor improved their heart condition.
"This study confirms what the medical community and the public already know about HRT and the treatment of heart disease," said Victoria Kusiak, MD, vice president, global medical affairs and North American medical director for Wyeth Pharmaceuticals, the study's sponsor.
"Consistent with the current position of the American Heart Association, my advice to physicians and women alike is not to initiate HRT solely to treat or prevent heart disease," said Dr. Michael Davidson, from the Rush Medical Center in Chicago, Illinois, a HERS II investigator.
Although the primary objective of HERS II was to ...
Source: HighBeam Research, HERS II finds HRT has neutral effect on preexisting heart disease.